ES2276405T3 - Ligandos de oligonucleotidos de alta afinidad a pdgf. - Google Patents

Ligandos de oligonucleotidos de alta afinidad a pdgf. Download PDF

Info

Publication number
ES2276405T3
ES2276405T3 ES96920573T ES96920573T ES2276405T3 ES 2276405 T3 ES2276405 T3 ES 2276405T3 ES 96920573 T ES96920573 T ES 96920573T ES 96920573 T ES96920573 T ES 96920573T ES 2276405 T3 ES2276405 T3 ES 2276405T3
Authority
ES
Spain
Prior art keywords
baselineskip
pdgf
ligands
sequence
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96920573T
Other languages
English (en)
Spanish (es)
Inventor
Penelope J. Toothman
Larry Gold
Nebojsa Janjic
Steven Ringquist
Nikos Pagratis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/458,424 external-priority patent/US5731424A/en
Priority claimed from US08/458,423 external-priority patent/US5731144A/en
Priority claimed from US08/465,594 external-priority patent/US5846713A/en
Priority claimed from US08/465,591 external-priority patent/US5837834A/en
Priority claimed from US08/479,725 external-priority patent/US5674685A/en
Priority claimed from US08/479,783 external-priority patent/US5668264A/en
Priority claimed from US08/618,693 external-priority patent/US5723594A/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ES2276405T3 publication Critical patent/ES2276405T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/13—Applications; Uses in screening processes in a process of directed evolution, e.g. SELEX, acquiring a new function
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES96920573T 1995-06-02 1996-05-30 Ligandos de oligonucleotidos de alta afinidad a pdgf. Expired - Lifetime ES2276405T3 (es)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US458424 1983-01-17
US465591 1983-02-10
US458423 1995-06-02
US08/458,424 US5731424A (en) 1990-06-11 1995-06-02 High affinity TGFβ nucleic acid ligands and inhibitors
US08/458,423 US5731144A (en) 1990-06-11 1995-06-02 High affinity TGFβ nucleic acid ligands
US08/465,594 US5846713A (en) 1990-06-11 1995-06-05 High affinity HKGF nucleic acid ligands and inhibitors
US08/465,591 US5837834A (en) 1990-06-11 1995-06-05 High affinity HKGF nucleic acid ligands and inhibitors
US465594 1995-06-05
US479783 1995-06-07
US479725 1995-06-07
US08/479,725 US5674685A (en) 1990-06-11 1995-06-07 High affinity PDGF nucleic acid ligands
US08/479,783 US5668264A (en) 1990-06-11 1995-06-07 High affinity PDGF nucleic acid ligands
US08/618,693 US5723594A (en) 1995-06-07 1996-03-20 High affinity PDGF nucleic acid ligands
US618693 1996-03-20
PCT/US1996/008014 WO1996038579A1 (en) 1995-06-02 1996-05-30 High-affinity oligonucleotide ligands to growth factors

Publications (1)

Publication Number Publication Date
ES2276405T3 true ES2276405T3 (es) 2007-06-16

Family

ID=27569790

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96920573T Expired - Lifetime ES2276405T3 (es) 1995-06-02 1996-05-30 Ligandos de oligonucleotidos de alta afinidad a pdgf.

Country Status (9)

Country Link
US (3) US6207816B1 (https=)
EP (2) EP1741780A3 (https=)
JP (2) JP4531132B2 (https=)
AT (1) ATE343638T1 (https=)
AU (1) AU732820B2 (https=)
CA (1) CA2221318C (https=)
DE (1) DE69636656T2 (https=)
ES (1) ES2276405T3 (https=)
WO (1) WO1996038579A1 (https=)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346611B1 (en) * 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
AU2004242462B2 (en) * 1999-07-29 2008-01-24 Gilead Sciences, Inc. Nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor C-Met and to integrins
US7300922B2 (en) 2001-05-25 2007-11-27 Duke University Modulators of pharmacological agents
US7879991B2 (en) * 2002-05-06 2011-02-01 Noxxon Pharma Ag CGRP binding nucleic acids
GB0213745D0 (en) 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
JP2005533794A (ja) * 2002-06-18 2005-11-10 アーケミックス コーポレイション アプタマー−毒素分子およびこれを使用する方法
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20040253243A1 (en) * 2003-01-21 2004-12-16 David Epstein Aptamer therapeutics useful in ocular pharmacotherapy
US8039443B2 (en) * 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US20050124565A1 (en) * 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
EP2924119A1 (en) 2003-04-21 2015-09-30 Archemix LLC Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20040219663A1 (en) * 2003-04-30 2004-11-04 Page Robert D. Biopolymer array fabrication using different drop deposition heads
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
PL3385384T3 (pl) 2004-02-12 2021-03-08 Archemix Llc Aptamerowe środki terapeutyczne użyteczne w leczeniu zaburzeń powiązanych z dopełniaczem
AU2005220910A1 (en) * 2004-03-05 2005-09-22 Archemix Corp. Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
US20080214489A1 (en) * 2004-04-19 2008-09-04 Anthony Dominic Keefe Aptamer-mediated intracellular delivery of oligonucleotides
US7579450B2 (en) * 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
JP2008512097A (ja) * 2004-09-07 2008-04-24 アーケミックス コーポレイション アプタマー医薬品化学
KR20070101227A (ko) 2004-09-07 2007-10-16 아케믹스 코포레이션 폰 빌레브란트 인자에 대한 앱타머 및 이의 혈전증치료제로서의 용도
EP3034089A1 (en) 2004-11-02 2016-06-22 Archemix LLC Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
CA2601400A1 (en) 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
KR20080025181A (ko) 2005-06-30 2008-03-19 아케믹스 코포레이션 완전 2'-변형된 핵산 전사체를 생성하기 위한 물질 및 방법
EP2368868A1 (en) 2005-10-28 2011-09-28 Praecis Pharmaceuticals Inc. Methods for identifying compounds of interest using encoded libraries
US7922000B2 (en) * 2006-02-15 2011-04-12 Miraial Co., Ltd. Thin plate container with a stack of removable loading trays
KR101584468B1 (ko) 2006-03-08 2016-01-13 아케믹스 엘엘씨 안질환의 치료에 유용한 보체 결합 앱타머 및 항-ｃ5 제제
WO2008134077A1 (en) * 2007-04-30 2008-11-06 Archemix Corp. Metabolic profile directed aptamer medicinal chemistry
US20090203766A1 (en) * 2007-06-01 2009-08-13 Archemix Corp. vWF aptamer formulations and methods for use
US20080305157A1 (en) * 2007-06-08 2008-12-11 University Of Maryland Office Of Technology Commercialization Encapsulation and separation of charged organic solutes inside catanionic vesicles
US20090233295A1 (en) * 2008-01-29 2009-09-17 Elias Georges Trim59 directed diagnostics for neoplastic disease
US8207298B2 (en) * 2008-05-01 2012-06-26 Archemix Corp. Methods of separating biopolymer conjugated molecules from unconjugated molecules
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
GB0904957D0 (en) 2009-03-23 2009-05-06 Univ Erasmus Medical Ct Tumour gene profile
GB0915515D0 (en) 2009-09-04 2009-10-07 Ucl Business Plc Treatment of vasculoproliferative conditions
US8841429B2 (en) * 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
US8236570B2 (en) 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
WO2011127933A1 (en) 2010-04-16 2011-10-20 Nuevolution A/S Bi-functional complexes and methods for making and using such complexes
GB201013573D0 (en) 2010-08-12 2010-09-29 Ucl Business Plc Treatment
GB201013785D0 (en) 2010-08-17 2010-09-29 Ucl Business Plc Treatment
GB201014026D0 (en) 2010-08-20 2010-10-06 Ucl Business Plc Treatment
WO2012038744A2 (en) 2010-09-22 2012-03-29 Genome Research Limited Detecting mutations
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
GB201120711D0 (en) 2011-12-01 2012-01-11 Univ Erasmus Medical Ct Method for classifying tumour cells
EP2802659A1 (en) 2012-01-10 2014-11-19 Noxxon Pharma AG Nucleic acids specifically binding cgrp
WO2013132267A1 (en) 2012-03-09 2013-09-12 Ucl Business Plc Treatment of cancer
CA2868096C (en) 2012-03-28 2019-12-31 Somalogic, Inc. Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions
GB201205739D0 (en) 2012-03-30 2012-05-16 Ucl Business Plc Treatment of acute inflammation in the respiratory tract
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
AU2014286996A1 (en) 2013-07-12 2016-01-07 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
US9695424B2 (en) 2013-09-09 2017-07-04 Somalogic, Inc. PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
WO2015140722A1 (en) 2014-03-17 2015-09-24 Glaxosmithkline Intellectual Property Development Limited Aptamers for topical delivery
US9605266B2 (en) 2014-07-16 2017-03-28 City Of Hope Cell-specific internalizing RNA aptamers against human CCR5 and uses therefore
CN107249644A (zh) 2014-10-15 2017-10-13 希望之城 针对转铁蛋白受体(TfR)的RNA适体
CN108290004A (zh) 2015-11-18 2018-07-17 福尔密孔股份公司 含有vegf拮抗剂的预填充塑料注射器
WO2018218013A2 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
CA3005132A1 (en) 2015-11-18 2017-05-26 Sio2 Medical Products, Inc. Coated syringe for ophthalmic formulations containing a vegf antagonist
WO2017087798A1 (en) 2015-11-18 2017-05-26 Formycon Ag Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
AU2017213103B2 (en) 2016-01-26 2022-08-11 Formycon Ag Liquid formulation of a VEGF antagonist
GB201704953D0 (en) 2017-03-28 2017-05-10 Imp Innovations Ltd Natural killer cells
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
WO2018217995A1 (en) 2017-05-24 2018-11-29 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
RU2020112854A (ru) 2017-11-30 2021-12-30 Арракис Терапьютикс, Инк. Фотозонды, связывающие нуклеиновые кислоты, и способы их применения
GB201804514D0 (en) 2018-03-21 2018-05-02 Ucl Business Plc Treatment of pyroptosis
GB201804515D0 (en) 2018-03-21 2018-05-02 Takayuki Takakondo Treatment of necroptosis
GB201804922D0 (en) 2018-03-27 2018-05-09 Ucl Business Plc Traatment
ES3018082T3 (en) * 2019-06-25 2025-05-14 Actome Gmbh Method and kit for measuring of analytes in bi-component systems and uses thereof
GB202002711D0 (en) 2020-02-26 2020-04-08 Ucl Business Ltd Treatment
IL299215A (en) 2020-06-25 2023-02-01 Medimmune Ltd Prevention of axonal damage through binding of an antibody to amyloid beta 1-42
US20240050389A1 (en) 2020-09-15 2024-02-15 Imperial College Innovations Limited Treatment of idiopathic pulmonary fibrosis
GB202017673D0 (en) 2020-11-09 2020-12-23 Imperial College Innovations Ltd Treatment of pulmonary arterial hypertensive
EP4475850A1 (en) 2022-02-09 2024-12-18 Imperial College Innovations Limited Treatment of telangiectasia
WO2024047368A1 (en) 2022-09-02 2024-03-07 Imperial College Innovations Limited Natural killer cells
GB202303784D0 (en) 2023-03-15 2023-04-26 Institute Of Cancer Res Royal Cancer Hospital Cancer treatment
WO2024261477A1 (en) 2023-06-20 2024-12-26 Yaqrit Limited Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
WO1989006694A1 (en) 1988-01-15 1989-07-27 Trustees Of The University Of Pennsylvania Process for selection of proteinaceous substances which mimic growth-inducing molecules
WO1991004748A1 (en) * 1989-09-29 1991-04-18 La Jolla Cancer Research Foundation INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5668264A (en) * 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5674685A (en) * 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5459015A (en) 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5837834A (en) * 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5846713A (en) * 1990-06-11 1998-12-08 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
ZA914750B (en) * 1990-06-20 1992-03-25 Bristol Myers Squibb Co Methods of modulating blood pressure using tgf-beta and antagonists thereof
CA2104698A1 (en) 1991-02-21 1992-08-22 John J. Toole Aptamers specific for biomolecules and methods of making
MX9301135A (es) * 1992-03-06 1993-09-01 Steven G Reed Metodo para tratar infecciones por patogeno de macrofago.
WO1993019783A1 (en) * 1992-04-01 1993-10-14 The Whittier Institute For Diabetes And Endocrinology Methods of inhibiting or enhancing scar formation in the cns
CA2155515A1 (en) * 1993-02-19 1994-09-01 Wendy Waegell Expansion of stem cells in long term bone marrow cultures by neutralization of tgf-.beta.
ATE235549T1 (de) * 1993-04-30 2003-04-15 Biognostik Ges Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2
CA2169536A1 (en) * 1993-09-08 1995-03-16 Gilead Sciences, Inc. Nucleic acid ligands and improved methods for producing the same
AU692185B2 (en) * 1993-09-17 1998-06-04 Somalogic, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex

Also Published As

Publication number Publication date
JP2007049997A (ja) 2007-03-01
JP2001500362A (ja) 2001-01-16
EP1741780A3 (en) 2007-03-28
WO1996038579A1 (en) 1996-12-05
US6207816B1 (en) 2001-03-27
EP0828849A4 (en) 2005-01-19
DE69636656D1 (de) 2006-12-07
CA2221318C (en) 2012-01-24
DE69636656T2 (de) 2007-10-04
CA2221318A1 (en) 1996-12-05
EP1741780A2 (en) 2007-01-10
JP4531132B2 (ja) 2010-08-25
US20060229273A1 (en) 2006-10-12
EP0828849B1 (en) 2006-10-25
EP0828849A1 (en) 1998-03-18
AU732820B2 (en) 2001-05-03
AU5883996A (en) 1996-12-18
US20030180744A1 (en) 2003-09-25
ATE343638T1 (de) 2006-11-15

Similar Documents

Publication Publication Date Title
ES2276405T3 (es) Ligandos de oligonucleotidos de alta afinidad a pdgf.
US5723594A (en) High affinity PDGF nucleic acid ligands
ES2426160T3 (es) Complejos de ligandos de ácidos nucleicos de factor de crecimiento derivado de plaquetas (PDGF)
US5731144A (en) High affinity TGFβ nucleic acid ligands
US5731424A (en) High affinity TGFβ nucleic acid ligands and inhibitors
US5846713A (en) High affinity HKGF nucleic acid ligands and inhibitors
US5668264A (en) High affinity PDGF nucleic acid ligands
US5674685A (en) High affinity PDGF nucleic acid ligands
US6124449A (en) High affinity TGFβ nucleic acid ligands and inhibitors
US6346611B1 (en) High affinity TGfβ nucleic acid ligands and inhibitors
NZ528077A (en) Use of tenascin-C nucleic acid ligands
US5837834A (en) High affinity HKGF nucleic acid ligands and inhibitors
AU773741B2 (en) High affinity oligonucleotide ligands to growth factors
AU2004206993B2 (en) High affinity oligonucleotide ligands to growth factors
US7005260B1 (en) Tenascin-C nucleic acid ligands